Price$22.24+0.23 (+1.04%)
03:00 PM07:45 PM
News · 26 weeks41+150%
2025-12-142026-06-07
Mix2890d
- Insider15(54%)
- SEC Filings8(29%)
- Earnings3(11%)
- Other1(4%)
- Analyst1(4%)
Latest news
25 items- INSIDERDirector Tanzberger Eric D was granted 5,308 shares, increasing direct ownership by 30% to 22,966 units (SEC Form 4)4 - Sanara MedTech Inc. (0000714256) (Issuer)
- INSIDERDirector Major Eric D was granted 4,846 shares, increasing direct ownership by 52% to 14,232 units (SEC Form 4)4 - Sanara MedTech Inc. (0000714256) (Issuer)
- INSIDERDirector Ortwein Sara N was granted 4,616 shares, increasing direct ownership by 22% to 25,415 units (SEC Form 4)4 - Sanara MedTech Inc. (0000714256) (Issuer)
- INSIDERDirector Nixon Ronald T was granted 4,154 shares, increasing direct ownership by 6% to 68,196 units (SEC Form 4)4 - Sanara MedTech Inc. (0000714256) (Issuer)
- INSIDERDirector Desutter Robert Andrew was granted 5,539 shares, increasing direct ownership by 24% to 28,740 units (SEC Form 4)4 - Sanara MedTech Inc. (0000714256) (Issuer)
- INSIDERDirector Salamone Ann Beal was granted 4,154 shares, increasing direct ownership by 18% to 26,858 units (SEC Form 4)4 - Sanara MedTech Inc. (0000714256) (Issuer)
- INSIDERDirector Mack Roszell Iii was granted 5,308 shares, increasing direct ownership by 32% to 21,842 units (SEC Form 4)4 - Sanara MedTech Inc. (0000714256) (Issuer)
- INSIDERDirector Myers Keith G was granted 4,385 shares, increasing direct ownership by 89% to 9,325 units (SEC Form 4)4 - Sanara MedTech Inc. (0000714256) (Issuer)
- SECSanara MedTech Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement8-K - Sanara MedTech Inc. (0000714256) (Filer)
- INSIDERChief Executive Officer Yon Seth D covered exercise/tax liability with 3,852 shares, decreasing direct ownership by 3% to 109,546 units (SEC Form 4) (for tax liability)4 - Sanara MedTech Inc. (0000714256) (Issuer)
- SECSEC Form 10-Q filed by Sanara MedTech Inc.10-Q - Sanara MedTech Inc. (0000714256) (Filer)
- SECSanara MedTech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Sanara MedTech Inc. (0000714256) (Filer)
- PRSanara MedTech Inc. Reports First Quarter 2026 Financial Results (Unaudited)Net Revenue Growth of 19% and Net Profitability from Continuing Operations of $0.04 Per Fully Diluted Share for the Quarter FORT WORTH, TX, May 11, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," "Sanara MedTech," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today reported its financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Summary(1) Net revenue increased 19% to $27.8 million, compared to $23.4 million in the first quarter of 2025.Gross profit of
- INSIDERAmendment: Controller Mackey Ashley M was granted 2,804 shares, increasing direct ownership by 130% to 4,967 units (SEC Form 4)4/A - Sanara MedTech Inc. (0000714256) (Issuer)
- SECSEC Form DEFA14A filed by Sanara MedTech Inc.DEFA14A - Sanara MedTech Inc. (0000714256) (Filer)
- SECSEC Form DEFA14A filed by Sanara MedTech Inc.DEFA14A - Sanara MedTech Inc. (0000714256) (Filer)
- SECSEC Form DEF 14A filed by Sanara MedTech Inc.DEF 14A - Sanara MedTech Inc. (0000714256) (Filer)
- INSIDERSEC Form 4 filed by Waldrop Jacob A.4 - Sanara MedTech Inc. (0000714256) (Issuer)
- ANALYSTLake Street initiated coverage on Sanara MedTech with a new price targetLake Street initiated coverage of Sanara MedTech with a rating of Buy and set a new price target of $32.00
- PRSanara MedTech Inc. to Report First Quarter 2026 Financial Results on May 12, 2026FORT WORTH, TX, April 14, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company", "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, announced today that it will report its first quarter 2026 financial results on Tuesday, May 12, 2026 before the U.S. financial markets open. The Company will host a conference call and webcast on May 12, 2026 at 8:00 a.m. Eastern Time to discuss the results of the quarter ended March 31, 2026 and hold a question and answer session at the end of the call. The toll-free numbe
- SECSEC Form 10-K filed by Sanara MedTech Inc.10-K - Sanara MedTech Inc. (0000714256) (Filer)
- SECSanara MedTech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Sanara MedTech Inc. (0000714256) (Filer)
- PRSanara MedTech Inc. Reports Fourth Quarter (Unaudited) and Full Year 2025 Financial Results; Reaffirmed Full Year 2026 Financial GuidanceFORT WORTH, TX, March 24, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today reported its financial results for the fourth quarter and full year ended December 31, 2025, and reaffirmed its financial guidance for the full year ending December 31, 2026. Fourth Quarter 2025 Financial Summary(1) Net revenue increased 5% to $27.5 million, compared to $26.3 million in the fourth quarter of 2024. As previously disclosed, the Company experienced growt
- INSIDERSEC Form 4 filed by Mackey Ashley M4 - Sanara MedTech Inc. (0000714256) (Issuer)
- INSIDERSEC Form 4 filed by Taylor Elizabeth B4 - Sanara MedTech Inc. (0000714256) (Issuer)
SMTI FAQ
6 questionsWhat does Sanara MedTech Inc. do?
Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical Activated Collagen Adjuvant powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako¯s Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako¯s Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes...Where does SMTI stock trade?
Sanara MedTech Inc. (SMTI) is listed on NASDAQ.What sector and industry is SMTI in?
Sanara MedTech Inc. operates in the Health Care sector, Industrial Specialties industry.What are analysts saying about SMTI?
Sanara MedTech Inc. has had 5 recent analyst actions on file. The most recent action was from Lake Street: Buy with a $3200.00 price target on 2026-04-15. Recent price targets range from $3200.00 to $4500.00.What companies are similar to SMTI?
Notable peers in the same industry include ISRG (Intuitive Surgical Inc.), EW (Edwards Lifesciences Corporation), STE (STERIS plc (Ireland)), ZBH (Zimmer Biomet Holdings Inc.), MAS (Masco Corporation). Compare SMTI side-by-side with any of them on Quantisnow.How can I track SMTI on Quantisnow?
Quantisnow aggregates Sanara MedTech Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SMTI to receive live email and push alerts on every new disclosure.